Shenzhen Neptunus Bioengineering Past Earnings Performance
Past criteria checks 0/6
Shenzhen Neptunus Bioengineering's earnings have been declining at an average annual rate of -72.6%, while the Healthcare industry saw earnings growing at 4.9% annually. Revenues have been declining at an average rate of 2.1% per year.
Key information
-72.6%
Earnings growth rate
-72.6%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | -2.1% |
| Return on equity | -41.4% |
| Net Margin | -5.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shenzhen Neptunus Bioengineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 34,549 | -1,722 | 2,350 | 47 |
| 31 Dec 23 | 36,419 | -1,690 | 2,540 | 48 |
| 30 Sep 23 | 37,520 | -1,071 | 2,729 | 48 |
| 30 Jun 23 | 39,667 | -1,053 | 2,855 | 45 |
| 31 Mar 23 | 38,591 | -1,024 | 2,873 | 48 |
| 31 Dec 22 | 37,835 | -1,027 | 2,860 | 48 |
| 30 Sep 22 | 39,234 | 12 | 2,544 | 28 |
| 30 Jun 22 | 38,937 | 67 | 2,706 | 41 |
| 31 Mar 22 | 40,121 | 73 | 2,751 | 38 |
| 01 Jan 22 | 41,054 | 93 | 2,781 | 39 |
| 30 Sep 21 | 42,053 | -275 | 3,004 | 52 |
| 30 Jun 21 | 42,395 | -276 | 2,890 | 43 |
| 31 Mar 21 | 42,091 | -276 | 2,934 | 43 |
| 31 Dec 20 | 40,022 | -289 | 2,753 | 38 |
| 30 Sep 20 | 39,535 | 41 | 2,957 | 50 |
| 30 Jun 20 | 38,508 | 131 | 2,953 | 38 |
| 31 Mar 20 | 39,013 | 153 | 3,009 | 39 |
| 31 Dec 19 | 41,493 | 206 | 3,140 | 42 |
| 30 Sep 19 | 41,260 | 348 | 3,256 | 44 |
| 30 Jun 19 | 41,681 | 292 | 3,261 | 48 |
| 31 Mar 19 | 39,723 | 394 | 3,126 | 55 |
| 31 Dec 18 | 38,381 | 415 | 3,012 | 45 |
| 30 Sep 18 | 36,608 | 657 | 2,747 | 61 |
| 30 Jun 18 | 33,269 | 727 | 2,496 | 70 |
| 31 Mar 18 | 29,954 | 697 | 2,160 | 50 |
| 01 Jan 18 | 24,940 | 636 | 1,868 | 50 |
| 30 Sep 17 | 19,593 | 602 | 1,511 | 17 |
| 30 Jun 17 | 16,468 | 554 | 1,283 | 0 |
| 31 Mar 17 | 14,667 | 471 | 1,204 | 0 |
| 31 Dec 16 | 13,606 | 418 | 1,165 | 0 |
| 30 Sep 16 | 13,065 | 352 | 1,134 | 0 |
| 30 Jun 16 | 12,081 | 520 | 1,107 | 0 |
| 31 Mar 16 | 11,572 | 487 | 1,131 | 0 |
| 31 Dec 15 | 11,118 | 475 | 1,114 | 0 |
| 30 Sep 15 | 10,809 | 320 | 1,090 | 0 |
| 30 Jun 15 | 10,505 | 26 | 1,091 | 0 |
| 31 Mar 15 | 10,177 | 25 | 1,041 | 0 |
| 31 Dec 14 | 9,802 | 24 | 1,040 | 0 |
| 30 Sep 14 | 9,293 | 113 | 994 | 0 |
| 30 Jun 14 | 8,922 | 119 | 1,015 | 0 |
| 31 Mar 14 | 8,427 | 119 | 956 | 0 |
| 31 Dec 13 | 7,993 | 117 | 913 | 0 |
| 30 Sep 13 | 7,568 | 57 | 850 | 0 |
| 30 Jun 13 | 7,060 | 60 | 741 | 0 |
Quality Earnings: 000078 is currently unprofitable.
Growing Profit Margin: 000078 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000078 is unprofitable, and losses have increased over the past 5 years at a rate of 72.6% per year.
Accelerating Growth: Unable to compare 000078's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000078 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-1%).
Return on Equity
High ROE: 000078 has a negative Return on Equity (-41.36%), as it is currently unprofitable.